



Procuring with Integrity

+264 (61) 447 700 pr@cpb.org.na www.cpb.org.na P.O. Box 23658 Mandume Park, 1 Tsinet Street, Windhoek, Namibia

PART A

NOTICE FOR SELECTION OF PROCUREMENT AWARD

(Section 55 of Act)

(Regulation 39(1))

AWARD NOTICE FOR	:	Supply and Delivery of Anti-Retroviral Medicine (ARVs) Products
Date:	:	28 April 2021
Procurement Reference No	:	G/OIB/CPBN-03/2020
Contract price	:	N\$314,626,280.20 Excluding VAT (DDP-CMS)
Name of successful bidder 1	:	Africure Pharmaceuticals Namibia
Address	:	208 Gold Street, Epic Park, Unit 8 Windhoek
Contract price	:	N\$3,640,520.27 Including VAT (DDP-CMS)
Name of successful bidder 2	:	Nampharm (PTY) Ltd
Address	:	12 Gold Street, Prosperita Windhoek

a) Kindly note that, in terms of Section 55 of the Public Procurement Act, 2015(Act No. 15 of 2015) and Regulation 39(1) of the Public Procurement Regulations, you have been selected for the award of this procurement contract referred to herein.

MEMBERS OF THE BOARD: Mr P.P. Swartz (Chairperson), Ms L. Ramakhutla (Deputy Chairperson), Ms J. IGarus-Oas, Ms E. Nghiidipaa, Ms H. Herman, Mr O. Nangolo, Mr E. Shilongo, Mr M. Kambulu, Mr A. Ngavetene, Ms E. Shiponeni (Secretary to the Board)

- b) Kindly further note that in the absence of application(s) for reconsideration of the selection for award with the Central Procurement Board of Namibia (CPBN), within the seven (7) days standstill period by any unsuccessful bidder(s), the Accounting Officer, in terms of Section 55(5) of the Public Procurement Act will award this Procurement Contract to you.
- c) The standstill period referred to in paragraph (b) starts on **30 April 2021 at 08H00 AM** and will end on **07 May 2021 at 17H00 PM** (Namibian Time).
- d) Any application(s) for reconsideration referred to in paragraph (b) above, can be forwarded to the following electronic mail address: Reconsiderations@cpb.org.na



PART B

NOTICE TO THE BIDDERS NOT SELECTED FOR AWARD

COSPHARM INVESTMENTS (PTY) LTD

MYLAN LABORATORIES LTD

AUROBINDO PHARMA (PTY) LTD

LAURUS LABS LIMITED

WINDHOEK MEDICAL SOLUTIONS

BROAD PHARMA (PTY) LTD

GECKA PHARMA (PTY) LTD

SUN PHARMACEUTICAL INDUSTRIES LTD

EMCURE PHARMACEUTICAL LTD

AFRIFARM INVESTMENTS (PTY) LTD

STRIDES PHARMA SCIENCE LIMITED

SALUTEM MEDICALS (PTY) LTD JV GREEN ENTERPRISES SOLUTIONS

NEW MEDICAL INVESTMENT HOLDINGS (PTY) LTD

HETERO LABS LIMITED

PART B

CIPLA QUALITY CHEMICAL INDUSTRIES LIMITED

SUPREMO PHARMACEUTICALS (PTY) LTD

- a) Kindly note that the bidders whose particulars are specified in PART A have been selected for the award.
- b) The prices offered by the bidders referred to in paragraph (a) are amounts of **N\$314,626,280.20** Excluding VAT (DDP-CMS) and **N\$3,640,520.27** Including VAT (DDP-CMS), respectively.
- c) The criteria used to select the award of the bidders referred to in paragraph (a) is set out in the bidding document reference number: **G/OIB/CPBN-03/2020**
- d) Kindly note that if you are not satisfied with the selection of award made by the Central Procurement Board of Namibia (CPBN), you may make an application for the reconsideration for the selection made with the CPBN within the seven (7) days of this notice, and in the absence of any application(s) for review, the Accounting Officer of CPBN shall award the contract to the person(s) selected for award.
- e) The standstill period of seven (7) days referred to in paragraph (d) starts on **30 April 2021 at 08H00 AM** and will end on **07 May 2021 at 17H00 PM** (Namibian Time).
- f) Any applications for reconsideration referred to in paragraph (d), can be forwarded to the following electronic mail address: Reconsiderations@cpb.org.na


P.P Swartz
Chairperson



RECEIPT ACKNOWLEDGEMENT FORM

**SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINE (ARVS) PRODUCTS
(PROCUREMENT REFERENCE NO. G/OIB/CPBN-03/2020)**

I/We _____ hereby
acknowledge receipt of this Notice of Procurement Award dated _____ and
undertake to immediately return it to CPBN as proof of receipt.

Name: Signature:

Date: Company Stamp:

EXECUTIVE SUMMARY OF THE BID EVALUATION REPORT (SECTION 55(8))

1.	Name of Procurement	Supply and Delivery of Anti-Retroviral Medicine (ARV'S) Products
2.	CPBN Procurement Reference No	G/OIB/CPBN-03/2020
3.	Date of Submission of Report	03 January 2021
4.	Contract Number	G/OIB/CPBN-03/2020
5.	Scope of Contract	Supply and Delivery of Anti-Retroviral Medicine (ARV'S) Products
6.	Estimated Cost:	N\$ 300,000,000 (Inc. VAT)
7.	Funding Agency	Ministry of Health and Social Services
8.	Procurement Method Used	Open International Bidding
9.	Date of Invitation of Bids	28 September 2020
10.	Closing Date of Submission of Bids	14 and 15 December 2020
11.	Date and Place of Opening of Bids	14 and 15 December 2020, at Central Procurement Board of Namibia
12.	Number of Bids Received by Closing Date	Eighteen (18) Bids



13. RESPONSIVENESS OF BID(S)

Bidder No.	Name of the Bidder(s)	Responsiveness as per evaluation stage				Responsiveness as per evaluation stage
		Conflict of Interest	Mandatory Documents	Technical Compliance	Financial Evaluation	
4	Cospharm Investments (Pty) Ltd	Not responsive & Disqualified	Not Considered	Not Considered	Not Considered	<ul style="list-style-type: none"> The Committee observed that Messrs Cosmas Mukaratirwa is appointed as the lawful agent to represent Bidder No. 10 Aurobindo Pharma (Pty) Ltd through a letter of authorization as extracted hereunder to "hand over the bidding document and all local liaison activities as part of this tender". At the same time Messrs Cosmas Mukaratirwa is bidding for the same bid as Bidder No.4 Cospharm Investments (Pty) Ltd, thus creating conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
7	Mylan Laboratories Ltd	Not responsive & Disqualified	Not Considered	Not Considered	Not Considered	<ul style="list-style-type: none"> Bidder No 7 Mylan Laboratories Ltd Issued a manufacturer authorization letter to Bidder No. 15 New Medical Investment Holdings (Pty) Ltd which is a participating Bidder in the same bid thus, creating conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
10	Aurobindo Pharma (Pty) Ltd	Not responsive & Disqualified	Not Considered	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bidder did not submit Founding statement to determine the shareholding and directors, the bidder was deemed non-responsive in accordance to criteria 2.1.1. Criteria 2.1.2 was not met. Bidder did not initial the Bid Form as required in criteria 2.1.2. The Bid Forms submitted by the bidder differs from that of form 5 in section VII on page 77-79 of the bidding document contrary to ITB 15.1, qualification criteria 2.1.2 and ITB 22.4.
16	Laurus Labs Limited	Not responsive & Disqualified	Not Considered	Not Considered	Not Considered	<ul style="list-style-type: none"> A representative by the name of Messrs. John Panduleni Alweendo of passport number PO741078 is appointed as the lawful agent to represent Bidder No. 16 Laurus Labs Limited, and at the same time he is the sole company owner of Bidder No. 18 Windhoek Medical Solutions both participating in this BID, thus creating conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
18	Windhoek Medical Solutions	Not responsive	Not Considered	Not Considered	Not Considered	<ul style="list-style-type: none"> A representative by the name of Messrs. John Panduleni Alweendo of passport number PO741078 is appointed as the lawful agent to represent

Bidder No.	Name of the Bidder(s)	Responsiveness as per evaluation stage				Responsiveness as per evaluation stage
		Conflict of Interest	Mandatory Documents	Technical Compliance	Financial Evaluation	
		Disqualified &				Bidder No. 16 Laurus Labs Limited, and at the same time he is the sole company owner of Bidder No. 18 Windhoek Medical Solutions both participating in this BID thus, creating conflict of interest in terms of ITB 5.4(d) on page 10 of the Bidding document.
1	Broad Pharma (Pty) Ltd	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bidder failed to submit product registration letter with NMRC or Authorization letter from NMRC to supply unregistered products, of which it was a mandatory requirement in terms of criteria 2.1.6 in the SBD.
3	Geka Pharma (Pty) Ltd	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bid Form submitted by the bidder differs from that of form 5 in section VII on page 77-79 of the SBD as the composition, format and order was changed contrary to criteria 2.1.2 and ITB 22.4 in the SBD. Bidder did not initial page 4 of a letter in book 1 of 3 with regard to this bid as required in evaluation criteria 2.1.2 on page 82 of the bidding document. The Bidder did not meet criteria 2.1.3 which is a requirement for Mandatory Documents for Namibian Bidders only. The Social Security Good Standing Certificate attached expired on 10 December 2020 and Bid Closed on 15 December 2020. The Bidder did not meet criteria 2.1.6 on Page 84 of the Bidding document as the Bidder did not submit Authorization letter from NMRC to supply unregistered product. The Bidder did not meet Instruction to Bidder (ITB) 33.4 (a) under the Bidding Data Sheet that stipulate that Health Sector Goods covered under this invitation are required to be delivered within 12 weeks after issue of Purchase order. Bidder has products indicating delivery beyond 12 weeks.
9	Sun Pharmaceutical Industries Ltd	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bidder failed to initial 10 pages in the annexures of World Health Organization (WHO), Agency Letter in terms of evaluation criteria 2.1.2 of the bidding document. The bidder did not meet the requirements of ITB 22.2 that required the original and all copies of the bid, to be typed or written in indelible ink and signed by the Bidder or a person or persons duly authorized. The bidder did not meet the requirements of ITB 15(1)(d) Written power of attorney or any other acceptable written evidence authorizing the signatory of the bid to commit the Bidder, as per clause 22.2. 2

Bidder No.	Name of the Bidder(s)	Responsiveness as per evaluation stage				Responsiveness as per evaluation stage
		Conflict of Interest	Mandatory Documents	Technical Compliance	Financial Evaluation	
11	Emcure Pharmaceutical Ltd.	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bidder provided the bid price in USD 14,411,903.90. This contravenes the Instruction to Bidders Clause 18.1 (b).
12	Afrifarm Investment (Pty) Ltd.	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The lease agreement submitted is not initialed by S. Hasselman who is given power of attorney signatory (authorised signatory) contrary to qualification criteria 2.1.2, ITB 22.2 and ITB 15.1(d) in the bidding document.
13	Strides Pharma Science Limited	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> The Bidder submitted an attachment that the magnitude of amounts/value in the documents of previous experience is erased neither was it initialed on erasure area. This contravenes ITB 22 (3).
14	Salutem Medicals (Pty) Ltd JV Green Enterprise Solutions	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> Power of attorney is not nominated by the JV and it was given for dealing with affairs of Namibia Defence Force (NDF) and not to deal with the CPBN bidding process. The Bid Securing Declaration is not in the name of the JV and format is not compliant with ITB 20.1. Bidder not in compliance with ITB 20.3 of the bidding document. No Letter by the JV as per ITB 5.2 that states that "all partners shall be jointly and severally liable".
15	New Medical Investment Holdings (Pty) Ltd	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> Bidder not compliant with ITB 20.1 of the bidding document. not in compliance with ITB 20.3 of the bidding document.
17	Hetero Labs Limited	Responsive	Not responsive & Disqualified	Not Considered	Not Considered	<ul style="list-style-type: none"> Hetero Labs Limited's entire bid submitted was not initialed by the authorised signatory which renders it not to be in compliance with ITB 22.2 and evaluation criteria 2.1.2 of the bidding document.
6	Cipla Quality Chemical Industries Limited	Responsive	Yes	Yes	No	<ul style="list-style-type: none"> On item No. 11, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours. On item No. 12, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours. On item No. 14, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.

Bidder No.	Name of the Bidder(s)	Responsiveness as per evaluation stage				Responsiveness as per evaluation stage
		Conflict of Interest	Mandatory Documents	Technical Compliance	Financial Evaluation	
8	Supremo Pharmaceuticals (Pty) Ltd	Responsive	Yes	Yes	Yes	<ul style="list-style-type: none"> On item No. 4, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours. On item No. 13, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours. On item No. 14, the bid was responsive, however, the successful Bidders had submitted the lowest substantial responsive bid compared to yours.
				Not responsive & Disqualified	Not considered	<ul style="list-style-type: none"> On item No. 5 the requirements stipulates that the items should be tablet dispersible and the Bidder offered tablets not dispersible contrary to ITB 33.3(c). On item No. 8 the requirements stipulates that the items should be tablet dispersible and the company offered tablets not dispersible according to the WHO prequalified brand for Micro Labs which the bidder indicated as their brand contrary to ITB 33.3(c).
				Not responsive & Disqualified	Not considered	<ul style="list-style-type: none"> On item No. 12 the bidder offered a product which is not a prequalified product according to the WHO prequalified list of products for Micro Labs which the bidder indicated as their brand contrary to ITB 33.3(c). On item No. 20 the requirements stipulates that the items should be oral granules, and the Bidder offered oral pellets contrary to ITB 33.3(c).
2	Nampharm (Pty) Ltd	Responsive	Yes	Not responsive & Disqualified	Not considered	<ul style="list-style-type: none"> On item No. 2 the requirements stipulates that the items should be 200mg Tablet, single scored, and the bidder offered capsules contrary to ITB 33.3(c). On item No. 16 the requirements stipulates that the items should be in 100 ml, and the bidder offered 200 ml contrary to ITB 33.3(c). Bidder not disqualified for items No. 3,6,17 and 18
5	Africare Pharmaceuticals Namibia	Responsive	Yes	Yes	Yes	<ul style="list-style-type: none"> Bidder not disqualified

14. TECHNICAL COMPLIANCE EVALUATION OF PRODUCTS OFFERED BY EACH QUALIFIED BIDDER (RESPONSIVE =R / NON-RESPONSIVE= NR)

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Nampharm (Pty) Ltd Bidder No. 2	Africure Pharmaceuticals Namibia Bidder No 5	Cipla Quality Chemical Industries Limited Bidder No 6	Supremo Pharmaceuticals (Pty) Ltd Bidder No 8
1	120824	Abacavir 300mg Tablet	60	4390	R	R	No quote	No quote
2	120722	Efavirenz 200mg Tablet, single scored	90	8530	NR	No quote	No quote	No quote
3	120772	Lamivudine 150mg Tablet	60	4390	R	No quote	No quote	No quote
4	120661	Lamivudine/Zidovudine 150/300mg tablet	60	90700	R	R	No quote	R
5	120820	Lamivudine/Zidovudine 30/60mg tablet, dispersible	60	13960	no quote	R	No quote	NR
6	120681	Lopinavir/Ritonavir 200/50mg tablet	120	2800	R	No quote	No quote	No quote
7	120652	Nevirapine 10mg/ml oral suspension, 100ml	1	46740	no quote	No quote	No quote	No quote
8	120646	Nevirapine 50mg tablet, dispersible	60	10700	no quote	No quote	No quote	NR
9	120821	Atazanavir/Ritonavir 300/100mg tablet	30	14380	no quote	R	No quote	No quote
10	120810	Tenofovir/Lamivudine/Efavirenz 300/300/400mg tablet (carton less packs)	30	310000	no quote	R	No quote	No quote
11	120698	Dolutegravir/Lamivudine/Tenofovir disoproxil fumarate 50/300/300mg tablet	30	335000	no quote	R	R	No quote
12	120699	Dolutegravir/Lamivudine/Tenofovir disoproxil fumarate 50/300/300mg tablet	90	60000	no quote	R	R	NR
13	120687	Emtricitabine/Tenofovir 200/300mg tablet	30	66510	R	R	No quote	R
14	120814	Lamivudine/Tenofovir 300/300mg tablet	30	4340	no quote	R	R	R
15	120812	Tenofovir 300mg tablet	30	4340	no quote	No quote	No quote	No quote
16	120701	Zidovudine 50mg/5ml Oral solution, 100ml	1	4900	NR	No quote	No quote	No quote

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Nampharm (Pty) Ltd Bidder No. 2	Africure Pharmaceuticals Namibia Bidder No 5	Cipla Quality Chemical Industries Limited Bidder No 6	Supremo Pharmaceuticals (Pty) Ltd Bidder No 8
17	120802	Zidovudine 300mg tablet	60	4340	R	No quote	No quote	No quote
18	120807	Ritonavir 100mg tablet	60	3650	R	No quote	No quote	No quote
19	120675	Abacavir/Lamivudine 120/60mg tablet, dispersible	30	35490	no quote	R	No quote	No quote
20	120683	Lopinavir/Ritonavir 40/10mg oral granules	120	36990	no quote	No quote	No quote	NR
21	120697	Dolutegravir 50mg tablet	30	35000	no quote	R	No quote	No quote
22	120781	Lopinavir/Ritonavir 100/25mg tablet	60	12390	R	R	No quote	No quote
23	120693	Darunavir 600mg tablet	60	2610	no quote	No quote	No quote	No quote
24	120779	Abacavir/Lamivudine 600/300mg tablet	30	122640	no quote	R	No quote	No quote
25	120700	Dolutegravir/Emtricitabine/Tenofovir alafenamide fumarate 50/200/25mg tablet (Carton less packs)	30	400000	no quote	R	No quote	No quote
26	120799	Raltegravir 100mg tablet, Chewable	60	400	no quote	No quote	No quote	No quote

15. FINANCIAL EVALUATION PER LINE ITEM QUALIFIED

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Nampharm (Pty) Ltd Bidder No. 2		Africure Pharmaceuticals Namibia Bidder No 5		Cipla Quality Chemical Industries Limited Bidder No 6		Supremo Pharmaceuticals (Pty) Ltd Bidder No 8	
					Unit Price	Total	Unit Price	Total	Unit Price	Total	Unit Price	Total
1	120824	Abacavir 300mg Tablet	60	4390	593.17	2,604,016.30	147.43	647,217.70	NQ	NQ	NQ	NQ
2	120722	Efavirenz 200mg Tablet, single scored	90	8530	NC	NC	NQ	NQ	NQ	NQ	NQ	NQ
3	120772	Lamivudine 150mg Tablet	60	4390	42.30	185,697.00	NQ	NQ	NQ	NQ	NQ	NQ
4	120661	Lamivudine/Zidovudine 150/300mg tablet	60	90700	159.55	14,471,185.00	95.95	8,702,665.00	NQ	NQ	146.52	13,289,364.00

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Nampharm (Pty) Ltd		Africure Pharmaceuticals Namibia		Cipla Quality Chemical Industries Limited		Supremo Pharmaceuticals (Pty) Ltd	
					Bidder No. 2		Bidder No 5		Bidder No 6		Bidder No 8	
					Unit Price	Total	Unit Price	Total	Unit Price	Total	Unit Price	Total
5	1208 20	Lamivudine/Zidovudine 30/60mg tablet, dispersible	60	13960	NQ	NQ	39.89	556,864.40	NQ	NQ	NC	NC
6	1206 81	Lopinavir/Ritonavir 200/50mg tablet	12 0	2800	588.00	1,646,400.00	NQ	NQ	NQ	NQ	NQ	NQ
7	1206 52	Nevirapine 10mg/ml oral suspension, 100ml	1	46740	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ
8	1206 46	Nevirapine 50mg tablet, dispersible	60	10700	NQ	NQ	NQ	NQ	NQ	NQ	NC	NC
9	1208 21	Atazanavir/Ritonavir 300/100mg tablet	30	14380	NQ	NQ	248.03	3,566,671.40	NQ	NQ	NQ	NQ
10	1208 10	Tenofovir/Lamivudine/Efavir enz 300/300/400mg tablet (carton less packs)	30	31000 0	NQ	NQ	93.40	28,954,000.00	NQ	NQ	NQ	NQ
11	1206 98	Dolutegravir/Lamivudine/Te nofovir disoproxil fumarate 50/300/300mg tablet	30	33500 0	NQ	NQ	90.85	30,434,750.00	104.00	34,840,000.00	NQ	NQ
12	1206 99	Dolutegravir/Lamivudine/Te nofovir disoproxil fumarate 50/300/300mg tablet	90	60000 0	NQ	NQ	254.73	152,838,000.00	296.00	177,600,000.00	NC	NC
13	1206 87	Emtricitabine/Tenofovir 200/300mg tablet	30	66510	376.32	25,029,043.20	84.74	5,636,057.40	-	-	104.39	6,942,978.90
14	1208 14	Lamivudine/Tenofovir 300/300mg tablet	30	4340	NQ	NQ	56.37	244,645.80	79.00	342,860.00	81.67	354,447.80
15	1208 12	Tenofovir 300mg tablet	30	4340	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ
16	1207 01	Zidovudine 50mg/5ml Oral solution, 100ml	1	4900	NC	NC	NQ	NQ	NQ	NQ	NQ	NQ
17	1208 02	Zidovudine 300mg tablet	60	4340	158.92	689,712.80	NQ	NQ	NQ	NQ	NQ	NQ
18	1208 07	Ritonavir 100mg tablet	60	3650	176.40	643,860.00	NQ	NQ	NQ	NQ	NQ	NQ
19	1206 75	Abacavir/Lamivudine 120/60mg tablet, dispersible	30	35490	NQ	NQ	53.49	1,898,360.10	NQ	NQ	NQ	NQ

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Nampharm (Pty) Ltd		Africare Pharmaceuticals Namibia		Cipla Quality Chemical Industries Limited		Supremo Pharmaceuticals (Pty) Ltd	
					Unit Price	Total	Unit Price	Total	Unit Price	Total	Unit Price	Total
20	1206 83	Lopinavir/Ritonavir 40/10mg oral granules	120	36990	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ
21	1206 97	Dolutegravir 50mg tablet	30	349,710	NQ	NQ	52.64	18,408,734.40	NQ	NQ	NQ	NQ
22	1207 81	Lopinavir/Ritonavir 100/25mg tablet	60	12390	157.58	1,952,416.20	138.76	1,719,236.40	NQ	NQ	NQ	NQ
23	1206 93	Darunavir 600mg tablet	60	2610	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ
24	1207 79	Abacavir/Lamivudine 600/300mg tablet	30	12264	NQ	NQ	148.59	18,223,077.60	NQ	NQ	NQ	NQ
25	1207 00	Dolutegravir/Emtricitabine/Tenofovir alafenamide fumarate 50/200/25mg tablet (Carton less packs)	30	40000	NQ	NQ	106.99	42,796,000.00	NQ	NQ	NQ	NQ
26	1207 99	Raltegravir 100mg tablet, Chewable	60	400	NQ	NQ	NQ	NQ	NQ	NQ	NQ	NQ

Key:

NC - Not Compliant

NQ - No Quotation

Given the recommendation(s) in the Bid Evaluation Committee (BEC) Report, the Board approved the bidder in the table below in terms of Section 9 (1) (k) and (l) (i) and Section 55 (6) of the Public Procurement Act, 2015

15.1. BIDDER NO.2 NAMPHARM (PTY) LTD

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Unit Price	Total N\$
3	120772	Lamivudine 150mg Tablet	60	4390	42.30	185,697.00
6	120681	Lopinavir/Ritonavir 200/50mg tablet	120	2800	588.00	1,646,400.00
17	120802	Zidovudine 300mg tablet	60	4340	158.92	689,712.80
18	120807	Ritonavir 100mg tablet	60	3650	176.40	643,860.00
SubTotal						3,165,669.80
VAT						474,850.47
Total						3,640,520.27

15.2. BIDDER NO.5 AFRICURE PHARMACEUTICALS NAMIBIA

Item No.	Stock Code	Product	Pack Size	Estimated quantity	Unit Price	Total N\$
1	120824	Abacavir 300mg Tablet	60	4390	147.43	647,217.70
4	120661	Lamivudine/Zidovudine 150/300mg tablet	60	90700	95.95	8,702,665.00
5	120820	Lamivudine/Zidovudine 30/60mg tablet, dispersible	60	13960	39.89	556,864.40
9	120821	Atazanavir/Ritonavir 300/100mg tablet	30	14380	248.03	3,566,671.40
10	120810	Tenofovir/Lamivudine/Efavirenz 300/300/400mg tablet (carton less packs)	30	310000	93.40	28,954,000.00
11	120698	Dolutegravir/Lamivudine/Tenofovir disoproxil fumarate 50/300/300mg tablet	30	335000	90.85	30,434,750.00
12	120699	Dolutegravir/Lamivudine/Tenofovir disoproxil fumarate 50/300/300mg tablet	90	600000	254.73	152,838,000.00
13	120687	Emtricitabine/Tenofovir 200/300mg tablet	30	66510	84.74	5,636,057.40
14	120814	Lamivudine/Tenofovir 300/300mg tablet	30	4340	56.37	244,645.80
19	120675	Abacavir/Lamivudine 120/60mg tablet, dispersible	30	35490	53.49	1,898,360.10
21	120697	Dolutegravir 50mg tablet	30	349,710	52.64	18,408,734.40
22	120781	Lopinavir/Ritonavir 100/25mg tablet	60	12390	138.76	1,719,236.40
24	120779	Abacavir/Lamivudine 600/300mg tablet	30	122640	148.59	18,223,077.60
25	120700	Dolutegravir/Emtricitabine/Tenofovir alafenamide fumarate 50/200/25mg tablet (Carton less packs)	30	400000	106.99	42,796,000.00
SubTotal						314,626,280.20
VAT						47,193,942.03
Total						361,820,222.23

16. ITEMS NOT AWARDED AND REASONS

Item No.	Product	Reasons
2	Efavirenz 200mg Tablet, single scored	The products were not awarded because there were no quotes received from the Technically qualified Bidders or the Bidders offered products which were not compliant with the requirements under ITB 8.1 of the bidding document
7	Nevirapine 10mg/ml oral suspension, 100ml	
8	Nevirapine 50mg tablet, dispersible	
15	Tenofovir 300mg tablet	
16	Zidovudine 50mg/5ml Oral solution, 100ml	
20	Lopinavir/Ritonavir 40/10mg oral granules	
23	Darunavir 600mg tablet	
26	Raltegravir 100mg tablet, Chewable	

17. PROPOSED AWARD OF CONTRACT

Description	Currency	Africure Pharmaceuticals Namibia
Bid Price	N\$	Amount Exclusive VAT (Delivery Duty Paid-CMS)
Bid Price(s) Read-Out	N\$	N\$314,624,515.31.
Corrections of Errors	N\$	N\$1,764.89
Discounts	N\$	None
Proposed Award	N\$	N\$ 314,626,280.20

Description	Currency	Nampharm (Pty) Ltd
Bid Price	N\$	Amount Inclusive VAT (Delivery Duty Paid-CMS)
Bid Price(s) Read-Out	N\$	N\$ 3,640,520.27
Corrections of Errors	N\$	None
Discounts	N\$	None
Proposed Award	N\$	N\$ 3,640,520.27

Central Medical Stores= CMS

Bidder No.	Bidder's Name	Address
2	Nampharm (Pty) Ltd	12 Gold street Prosperita Windhoek
5	Africure Pharmaceuticals Namibia	208 Gold Street Epic Park Unit 8 Windhoek

28 April 2021



P.P. Swartz
Chairperson

